Selargius

This research aims to collect mid-term post-market clinical follow-up data on the GORE4 TAG4 Thoracic Branch Endoprosthesis device used in patients with thoracic vascular diseases such as aneurysm, aortic dissection, thoracoabdominal aortic aneurysm, thoracic aortic aneurysm, and aortic transection. The study focuses on understanding the safety and effectiveness of this device when used according to standard medical practice in real-world settings. Participants in this observational registry will receive treatment with the GORE4 TAG4 Thoracic Branch Endoprosthesis device as determined by their physicians based on usual clinical care. The registry includes only patients treated with at least the TBE aortic component of the device. Treatment decisions, diagnostic imaging, and interventions follow standard care without imposed protocol restrictions. Patients will be monitored over time to evaluate outcomes related to the device and procedure. During the study, participants will attend regular follow-up visits as advised by their surgeons to report any device- or surgery-related issues. The study will track important outcomes such as technical success of device deployment during surgery, mortality related to the treated lesion from 30 days to 2 years, lesion rupture or enlargement, device migration, endoleaks, stroke, paralysis, renal function changes, device integrity, and need for reintervention. These assessments ensure comprehensive monitoring of patient safety and device performance for up to 2 years post-surgery.